2025Year4Month14Day, Johnson & Johnson Medical Technology Company (Johnson & Johnson MedTech) Announced,Developed byOttavaThe surgical robot platform has successfully completed the first batch of clinical cases, marking a critical step forward for this innovative technology in the field of minimally invasive surgery.This surgery was performed byUT Health HoustonDirector of Minimally Invasive Surgery and Elective General SurgeryErik WilsonDoctor in charge of the operation, inMemorial Hermann-Texas Medical CenterCompleted one caseRoux-en-YGastric Bypass Surgery.

As the world's first based onOttavaClinical Application Cases of the Platform,WilsonDr. stated: "Surgical robot technology is at the core of minimally invasive surgery innovation, and being able to participateOttava"The first clinical study and the promotion of industry standards make me feel deeply proud." This breakthrough highlightsOttavaThe potential in multi-specialty soft tissue surgeries, designed to eliminate collaboration barriers in traditional robotic surgery, providing surgical teams with greater flexibility and personalized operating space.

OttavaIt is a multi-specialty soft tissue surgical robot that supports multi-quadrant operational needs for complex surgeries. Its core innovations include:

• Six-arm Collaborative Design: By integrating six mechanical arms,OttavaCapable of adapting to patient anatomy and surgical specialty requirements, covering upper abdominal general surgeries such as gastric bypass, sleeve gastrectomy, small bowel resection, and hiatal hernia repair.

  
  

• Integrated Operating Table: Four robotic arms are embedded in a standard-sized operating table, achieving an "invisible design." They unfold when needed and retract under the table when not in use, optimizing the utilization of operating room space.

  
  

• Clinical Workflow Adaptation: The system allows surgical teams to adjust operational procedures according to actual needs, enhancing surgical efficiency and safety.

Johnson & Johnson plans to further validate based on the data from this clinical evaluation.OttavaPerformance in a variety of surgical scenarios, and submitFDAReauthorization Application.Chairman of the Company's Surgical DepartmentHani AbouhalkaEmphasized: "Ottava"It is a key innovation in our advanced surgical technology portfolio, aimed at reshaping the surgical experience and raising the standard of care for patients worldwide."

Johnson & Johnson disclosed for the first time in the middle of four years agoOttavaSince the platform details were released, it has been committed to challenging Intuitive Surgical's long-standing dominance in the soft tissue robotics field. Despite2021The development progress was postponed in the year due to multiple factors, but the company eventually achieved it through continuous design optimization.2024Year10Monthly SubmissionIDEApply, and obtain the following monthFDAApproval to initiate the study.

Chief Scientific Officer of Johnson & Johnson Medical TechnologyPeter Schulam"The generation of clinical evidence is at the core of our innovation plan. Through this research, we look forward to collaborating with surgeons to provide a scientific basis for the development of robot-assisted minimally invasive surgery." This strategy reflects Johnson & Johnson's long-term commitment to the intersection of biology and technology.

This clinical breakthrough marksOttavaAn important turning point from R&D to practical application, which may reshape the competitive landscape of the soft tissue surgical robot market in the future.